DexCom DXCM recently announced the upcoming Canadian launch of its Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) ...

Dexcom's landmark CONNECT trial, now published in the NEJM, could drive a pivotal CMS coverage decision for type 2 diabetes patients this year.

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The New England Journal of Medicine. The CONNECT study focused on adults with ...

DexCom reported third-quarter 2026 revenue of $1.34 billion, up 11% year-over-year on both a reported and organic basis, powered by a 14% jump in ...

Dexcom topped Wall Street’s expectations for third-quarter earnings, and the company nudged up its guidance for the remainder ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Net Income and Diluted Net Income Per Share: GAAP net income was $275.1 million, or $0.72 per diluted share, for the third ...

A list of domestic and international medical and healthcare news for the past week, along with brief commentary. On October ...

In the CONNECT trial, CGM users with type 2 diabetes not on insulin saw larger A1C reductions and more time in range than ...

Medical device company DexCom (NASDAQ:DXCM) reported in Q3 2026, with sales up 11.2% year on year to $1.34 billion. The ...

Dexcom raised full-year revenue guidance again, to $5.20 billion to $5.25 billion, after topping expectations on both lines.